Health Insurance (Facial Injections of Poly-L-lactic acid) Determination 2011

Overview

The Health Insurance (Facial Injections of Poly-L-lactic acid) Determination 2011, enacted under the Health Insurance Act 1973, was introduced to address the gap in Medicare coverage for the treatment of severe facial lipoatrophy in HIV-positive patients caused by antiretroviral therapy. This legislation, issued by the Authority of the Minister for Health and Ageing, aims to enable the payment of Medicare benefits for the specific medical procedure involving the injection of poly-L-lactic acid (Sculptra®). Two new Medicare Benefits Schedule (MBS) items were created to cover the initiation of treatment and subsequent injection sessions, aligning with the Pharmaceutical Benefits Scheme (PBS) restrictions. This Determination was enacted to ensure that eligible patients receive necessary treatments through accredited injectors, following referrals from HIV physicians, thereby providing a comprehensive healthcare solution for this specific medical condition.

Scope and Application

The Health Insurance (Facial Injections of Poly-L-lactic acid) Determination 2011 applies to the treatment of severe facial lipoatrophy in HIV positive patients caused by antiretroviral therapy, specifically through the use of poly-L-lactic acid injections (Sculptra®). This Determination enables the payment of Medicare benefits for this procedure by treating it as if it were listed in the general medical services table of the Health Insurance Act 1973. The Act applies to eligible patients who are referred by an HIV physician to an accredited injector. The Determination specifies that two new Medicare Benefits Schedule items will cover the initiation of treatment and subsequent injection sessions, subject to certain limitations such as the maximum number of treatments. The Determination has a national reach and applies across Australia, commencing on 1 July 2011 and remaining in force until 31 October 2011. The application of these items is further restricted to accredited injectors who have completed specific training with the manufacturer of Sculptra®. This Determination extends the Act by incorporating the specified health services under the Medicare Benefits Schedule, thereby allowing for the provision of these services to eligible patients within the given timeframe and under the outlined conditions.

Key Provisions

The Health Insurance (Facial Injections of Poly-L-lactic acid) Determination 2011, issued under the Health Insurance Act 1973, primarily focuses on the treatment of severe facial lipoatrophy caused by antiretroviral therapy in HIV positive patients. This is achieved through the injection of poly-L-lactic acid (Sculptra®). Two new Medicare Benefits Schedule (MBS) items are introduced to facilitate this: item 14201 for the initiation of treatment, limited to one injection session, and item 14202 for subsequent injection sessions, up to a maximum of four adjustment treatments, followed by one maintenance injection session every two years (subsection 4(a)). The fees for these services are specified in the Schedule to the Determination (subsection 4(b)). The Determination imposes specific obligations on the parties involved. For instance, only accredited injectors are permitted to provide the services under the Determination, and they must complete injection administration training with Sanofi-Aventis, the manufacturer of Sculptra® (section 5). Additionally, patients must be referred from their HIV physician to an accredited injector. The MBS items are designed to align with Pharmaceutical Benefits Scheme (PBS) restrictions, such as the maximum number of treatments, and require that Sculptra be prescribed under the PBS. There are no specific offences, penalties, or civil/criminal consequences outlined within the Determination itself. However, breaches of the conditions set out in the Determination could potentially lead to legal repercussions under the Health Insurance Act 1973 or other relevant legislation. The Determination is a legislative instrument for the purposes of the Legislative Instruments Act 2003, and it commences on 1 July 2011, remaining in force until 31 October 2011 (section 2). During this period, compliance with the terms and conditions outlined is essential to ensure the proper administration and reimbursement of these medical services.